Orphan drugs are treatments for rare diseases, including rare forms of cancer. Regulatory bodies have specific incentives and regulations to encourage the development of orphan drugs, such as market exclusivity, tax credits, and grants. These incentives aim to address the unique challenges in developing treatments for rare conditions, ensuring that patients with rare cancers have access to effective therapies.
